| Literature DB >> 30149535 |
Shi-Jie Liu1, Zhanbing Ren2, Lin Wang3, Gao-Xia Wei4, Liye Zou5.
Abstract
Baduanjin exercise is a traditional Chinese health Qigong routine created by an ancient physician for health promotion. Its mild-to-moderate exercise intensity is suitable for individuals with medical conditions. Recently, a large number of trials have been conducted to investigate the effects of Baduanjin exercise in patients with chronic obstructive pulmonary disease (COPD). It remains to be determined whether Baduanjin exercise prescription is beneficial for the management of COPD patients. Thus, we conducted a systematic review to objectively evaluate the existing literature on this topic. We searched six databases (PubMed, Web of Science, Cochrane Library, Scopus, China National Knowledge Infrastructure, and Wanfang) from inception until early May 2018. The adapted Physical Therapy Evidence Database (PEDro) scale was used for study quality assessment of all randomized controlled trials (RCTs). Based on 95% confidence interval (CI), the pooled effect size (Hedge's g) of exercise capability (6-Minute Walking Test, 6-MWT), lung function parameters (forced expiratory volume in one second, FEV₁; forced volume vital capacity, FVC; FEV₁/FVC ratio), and quality of life were calculated based on the random-effects model. Twenty RCTs (n = 1975 COPD patients) were included in this review, with sum scores of the adapted PEDro scale between 5 and 9. Study results of the meta-analysis indicate that Baduanjin is effective in improving exercise capability (Hedge's g = 0.69, CI 0.44 to 0.94, p < 0.001, I² = 66%), FEV₁ (Hedge's g = 0.47, CI 0.22 to 0.73, p < 0.001, I² = 68.01%), FEV₁% (Hedge's g = 0.38, CI 0.21 to 0.56, p < 0.001, I² = 54.74%), FVC (Hedge's g = 0.39, CI 0.22 to 0.56, p < 0.001, I² = 14.57%), FEV₁/FVC (Hedge's g = 0.5, CI 0.33 to 0.68, p < 0.001, I² = 53.49%), and the quality of life of COPD patients (Hedge's g = -0.45, CI -0.77 to -0.12, p < 0.05, I² = 77.02%), as compared to control groups. Baduanjin exercise as an adjunctive treatment may potentially improve exercise capability and pulmonary function of COPD patients as well as quality of life. Baduanjin exercise could be tentatively prescribed for COPD in combination with the conventional rehabilitation program to quicken the process of recovery. To confirm the positive effects of Baduanjin exercise for COPD patients, future researchers need to consider our suggestions mentioned in this article.Entities:
Keywords: Baduanjin; COPD; Qigong; rehabilitation
Mesh:
Year: 2018 PMID: 30149535 PMCID: PMC6165467 DOI: 10.3390/ijerph15091830
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow of study selection.
Summary of randomized controlled trials.
| Reference | Location | Participant Characteristics | Intervention Program | Baduanjin Training | Outcome | Adverse Event; | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sample Size | Mean Age or Age Range | Course of Disease | Frequency | Time | Duration | |||||
| Zhang et al. [ | Changchun, | 60 (0%) | BJ: 68.50 (9.18) | NR | BJ: Baduanjin + Drug Therapy | 7 | / | 8 | Lung function (FEV1, FEV1%, FVC), | No; |
| Deng et al. [ | Fujian, | 60 (1.6%) | BJ: 66.26 (5.13) | BJ: 4.68 (2.54) | BJ: Baduanjin + Usual Care | 7 | 30 | 12 | Lung function | No; |
| Liang et al. [ | Guangdong, | 82 (0%) | BJ: 60.23 (9.32) | BJ: 4.25 (2.05) | BJ: Baduanjin + Usual Care | 7 | 30 | 12 | Lung function | No; |
| Chen et al. [ | Fujian, | 60 (3.4%) | BJ: 66.26 (5.13) | BJ: 4.68 (2.54) | BJ: Baduanjin + Usual Care | 7 | 30 | 12 | Exercise Capacity (6-MWT), | No; |
| Yin et al. [ | Guangzhou, | 24 (0%) | BJ: 70.40 (7.56) | NR | BJ: Baduanjin + Drug Therapy | 7 | 30 | 24 | Quality of life (SGRQ), | No; |
| Hou et al. [ | Dongwan, | 60 (0%) | BJ: 63.34 (5.95) | NR | BJ: Baduanjin + Breathing Training | 2 | 30 | 12 | Lung function (FEV1, FVC, FEV1/FVC), | No; |
| Guo, Gao et al. [ | Qingdao, | 60 (0%) | BJ: 63.4 (NR) | BJ: 4.67 (1.54) | BJ: Baduanjin + Drug Therapy | >4 | 30 | 24 | Lung function (FEV1, FEV1%, FVC, FEV1/FVC) | No; |
| Guo et al. [ | Qingdao, | 320 (0%) | BJ: 64.87 (8.86) | BJ: 16.19 (5.48) | BJ: Baduanjin + Drug Therapy | >4 | 30 | 24 | Lung function (FEV1%, FEV1/FVC), | No; |
| Liu et al. [ | Chengdu, | 80 (0%) | BJ: 59.77 (7.08) | NR | BJ: Baduanjin + Usual Care | 7 | 30 | 12 | Lung function (FEV1%, FEV1/FVC), | No; |
| Chen, Liu et al. [ | Chengdu, | 78 (0%) | BJ: 60.52 (7.24) | NR | BJ: Baduanjin + Usual Care | 7 | 30 | 12 | Lung function (FEV1%, FEV1/FVC) | No; |
| Huang et al. [ | Nanjing, | 62 (0%) | BJ: 68.24 (3.28) | BJ: 24.60 (10.6) | BJ: Baduanjin + Drug Therapy | 7 | 30 | 24 | Lung function (FEV1, FEV1%, FEV1/FVC) | No; |
| Wang, Fang et al. [ | Dalian, | 73 (3.9%) | BJ: 63.17 (9.95) | BJ: 15.17 (6.73) | BJ: Baduanjin + Drug Therapy | 7 | 30 | 12 | Lung function (FEV1, FEV1%, FVC, | No; |
| Pan et al. [ | SiChuan, | 82 (0%) | BJ: 60.7 (5.6) | BJ: 6.7 (6.2) | BJ: Baduanjin + Usual Care | 7 | 30 | 24 | Lung function (FEV1, FEV1%, FVC, FEV1/FVC), Exercise Capacity (6-MWT), | No; |
| Wang [ | Beijing, | 73 (0%) | BJ: 66.76 (5.80) | BJ: 11.02 (3.38) | BJ: Baduanjin + Drug Therapy | 7 | 30 | 48 | Lung function (FEV1%, FEV1), | No; |
| Zhu et a. [ | ChangSha, | 125 (0%) | BJ: 69.00 (8.70) | BJ: 12.50 (10.70) | BJ: Baduanjin + Drug Therapy | 14 | 30 | 24 | Lung function (FEV1, FEV1%, FVC, FEV1/FVC), Exercise Capacity (6-MWT) | No; |
| Sun et al. [ | ChangChun, | 60 (5.4%) | BJ: 62.97 (6.87) | BJ: 11.02 (3.38) | BJ: Baduanjin + Drug Therapy | 7 | 30 | 48 | Lung function (FEV1%) , Exercise Capacity (6-MWT) and Quality of life (CAT) | No; |
| Feng et al. [ | GuangZhou, | 60 (0%) | BJ: 63 (4.00) | BJ: 5.2 (2.2) | BJ: Baduanjin + Conventional Therapy | 10 | 45 | 24 | Lung function (FEV1, FEV1%, FVC, | No; |
| Lv et al. [ | Beijing, | 160 (0%) | BJ: 64.88 (8.87) | BJ: 16.21 (5.49) | BJ: Baduanjin + Conventional Therapy | 7 | 20 | 2 | Exercise Capacity (6-MWT), | No; |
| Bobby et al. [ | Hong kong, | 51 (36.25%) | BJ: 71.75 (1.05) | NR | BJ: Baduanjin | >4 | 30 | 24 | Exercise Capacity (6-MWT) | No; |
| Liu et al. [ | ShangHai, | 132 (10.60%) | BJ: 61.82 (7.69) | BJ: 7.54 (2.73) | BJ: Baduanjin | 3 | 60 | 24 | Lung function (FEV1%, FEV1/FVC), | No; |
Note: BJ = Baduanjin; CG = control group; FEV1 = the forced expiratory volume in one second; FEV1% = percentage of the forced expiratory volume in one second; FVC = forced vital capacity; FEV1/FVC = the amount of air exhaled in the first second divided by all of the air exhaled during a maximal exhalation; 6-MWT = 6-Minute Walking Test; SGRQ = St. George’s Breathing Questionnaire; CAT = COPD (chronic obstructive pulmonary disease) Assessment Test; NR = not reported.
Study quality assessment for eligible randomized controlled trials.
| Author [Reference] | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Item 7 | Item 8 | Item 9 | Score |
|---|---|---|---|---|---|---|---|---|---|---|
| Zhang et al. [ | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 7 |
| Deng et al. [ | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Liang et al. [ | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 5 |
| Chen et al. [ | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Yin et al. [ | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 6 |
| Hou et al. [ | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 5 |
| Guo, Gao et al. [ | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Guo et al. [ | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Liu et al. [ | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Chen, Liu et al. [ | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 7 |
| Huang et al. [ | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Wang, Fang et al. [ | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Pan et al. [ | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Wang [ | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Zhu et al. [ | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 7 |
| Sun et al. [ | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 7 |
| Feng et al. [ | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 7 |
| Lv et al. [ | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Bobby et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 7 |
| Liu et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
Note: Item 1 = randomization; Item 2 = concealed allocation; Item 3 = similar baseline; Item 4 = blinding of assessors; Item 5 = more than 85% retention; Item 6 = missing data management (intention-to-treat analysis); Item 7 = between-group comparison; Item 8 = point measure and measures of variability; Item 9 = isolated Baduanjin intervention; 1 = explicitly described and present in details; 0 = absent, inadequately described, or unclear.
Figure 2Funnel plot of publication bias for the 6-Minute Distance Test.
Figure 3Effects of Baduanjin on exercise capability measured by the 6-MWT (BT = breathing technique; PRP = conventional pulmonary rehabilitation; UC = usual care).
Figure 4Funnel plot of publication for FEV1.
Figure 5Effect of Baduanjin on FEV1 (BT = breathing technique training).
Study results of meta-analysis regarding lung function parameters.
| Outcomes | Studies | Sample Size | Hedge’s g | 95% CI | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
| Baduanjin Group | Control Group | ||||||
| FEV1 value | 10 | 398 | 411 | 0.47 | 0.22–0.73 | 68.01% | |
| FEV1% value | 13 | 711 | 706 | 0.38 | 0.21–0.56 | 54.74% | |
| FVC | 8 | 330 | 344 | 0.39 | 0.22–0.56 | 14.57% | |
| FEV1/FVC value | 13 | 629 | 655 | 0.5 | 0.33–0.68 | 53.49% | |
Note: Lung functions consisted of FEV1 (forced expiratory volume in one second, n = 12 RCTs), FEV1% (n = 16 RCTs), FVC (forced vital capacity, n = 10 RCTs), and FEV1/FVC (n = 14 RCTs).
Figure 6Funnel plot of publication bias for FEV1%.
Figure 7Effects of Baduanjin on FEV1% (PRP = conventional-pulmonary rehabilitation programs; UC = usual care).
Figure 8Funnel plot of publication bias for FVC.
Figure 9Effects of Baduanjin on FVC (BT = breathing technique training).
Figure 10Funnel plot of publication bias for FEV1/FVC%.
Figure 11Effects of Baduanjin on FEV1/FVC% (BT = breathing technique training; UC = usual care).
Figure 12Funnel plot of publication bias for quality of life.
Figure 13Effects of Baduanjin on quality of life of COPD patients.